Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing. The oversubscribed round was led by Viking Global Investors and included…
Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary…
Say goodbye to plants: Synbio player Antheia earns new backers in quest to redesign flora-derived…
The age of synthetic biology is officially upon us with super-unicorns like Ginkgo Bioworks changing the game in terms of how investors view those cell engineering platforms…
Synthetic-Biology Startup Antheia Raises $73 Million
Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new venture-capital financing…
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia’s first pharmaceutical compounds to market, expand its pipeline and scale production in global markets…